Protalix Biotherapeutics, Inc.
2 Snunit Street, Science Park
P.O. Box 455
Karmiel
21000
Tel: 972-4-988-9488
Fax: 972-4-988-9489
Website: http://www.protalix.com/
Email: info@protalix.com
244 articles with Protalix Biotherapeutics, Inc.
-
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease
6/2/2021
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthare Group, provided an update regarding the clinical development of pegunigalsidase alfa for the proposed treatment of Fabry disease.
-
Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business Update
5/14/2021
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the first quarter ended March 31, 2021
-
Protalix BioTherapeutics to Hold First Quarter 2021 Financial and Business Results Conference Call on May 14, 2021
5/7/2021
Company to host conference call and webcast at 8:30 a.m. EDT
-
The U.S. FDA approved Chiesi Global Rare Diseases’ Ferriprox for treatment of transfusional iron overload caused by sickle cell disease (SCD) or other anemias in adults and children ages three years and older. This approval expands the use of the drug for patients with SCD or other anemias.
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
4/28/2021
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced that they received a Complete Response Letter from the U.S. Food and Drug Administration regarding the Biologics License Application seeking accelerated approval of pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease.
-
Protalix BioTherapeutics Provides Update on Complete Response Letter for Pegunigalsidase Alfa from the FDA
4/28/2021
Protalix BioTherapeutics, Inc. today provided an update regarding the Complete Response Letter (CRL) received from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) seeking accelerated approval of pegunigalsidase alfa (PRX–102) for the proposed treatment of adult patients with Fabry disease. Receipt of the CRL was announced earlier today.
-
The U.S. Food and Drug Administration’s schedule for April has several PDUFA dates scattered across the rest of the month. Here’s a look.
-
Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results
3/30/2021
Successfully raised approximately $40 million in gross proceeds in an equity offering led by BofA Securities and Oppenheimer
-
Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021
3/22/2021
Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, announced that it will release its financial results for fiscal year 2020 and business update on Tuesday, March 30, 2021.
-
Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
3/4/2021
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced today announced that the Company's management will participate and present a corporate overview at the H.C. Wainwright Global Life Sciences Conference,
-
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
-
Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds
2/18/2021
Anticipated PDUFA for PRX-102 in Fabry disease currently set for April 27, 2021 Company, with its Commercialization Partner, Chiesi, poised to commercialize PRX-102 Additional data and milestones expected throughout 2021
-
Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery
2/11/2021
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced an exclusive worldwide license agreement with SarcoMed USA Inc. for alidornase alfa, or PRX–110
-
Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock
2/11/2021
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it intends to make a public offer of 6,500,000 shares
-
Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common Stock
2/11/2021
Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX) (the "Company"), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system,
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLD Symposium™ 2021
2/10/2021
Protalix BioTherapeutics today announced that final results from the Phase III BRIDGE clinical trial (NCT03018730) of pegunigalsidase alfa (PRX–102)
-
Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021
2/1/2021
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will deliver an oral presentation and a poster presentation at the 17th Annual WORLDSymposium
-
Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in January
1/4/2021
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that the Company's management will participate in virtual 1x1 investor meetings
-
Protalix BioTherapeutics Issues 2020 Letter to Shareholders
12/30/2020
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today announced the following letter from its Presiden
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
12/30/2020
A decline trend in patients' renal function on agalsidase alfa was attenuated and improved to be similar to normal renal function decline when switched to PRX-102